Labcorp introduces US FDA approved blood test, Lumipulse pTau-217/Beta Amyloid 42 Ratio for Alzheimer's disease: Burlington, North Carolina Tuesday, August 19, 2025, 14:00 Hrs [IS ...

LH launches the first FDA-cleared blood test for Alzheimer's, boosting access to early diagnosis and nudging its stock higher.

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the availability of the Lumipulse® pTau-217/Beta Amyloid 42 Ratio, the first blood-based ...

Labcorp has launched the first blood-based in-vitro diagnostic test cleared by the Food and Drug Administration to aid in the diagnosis of Alzheimer's disease.

Seniors experiencing memory problems and cognitive decline now have access to a new diagnostic blood test to detect Alzheimer’s disease. Labcorp this week unveiled the first Food and Drug ...

Rates of diagnosis and treatment are low, so there is need for diagnostic tests and biomarkers for classification and ...

The Alzheimer's Association released its first comprehensive clinical practice guidelines for the diagnosis, treatment, and ...

Prenatal exposure to chlorpyrifos -- mostly attributable to indoor residential spraying for pests, prevalent in inner-city ...

The blood test, Lumipulse G, for Alzheimer’s Disease, approved in late May, can confirm the disease with 98 percent accuracy, he said. Prior to the blood test, doctors confirmed the disease by drawing ...

The blood test, Lumipulse G, for Alzheimer's Disease, approved in late May, can confirm the disease with 98 percent accuracy, he said.

FutureWise Research today announces the upcoming release of its comprehensive report, Alzheimer’s Disease Diagnostic Market – ...